Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Indiva Reports Fiscal Year 2023 Results Including Record Positive EBITDA and Income (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Appili Therapeutics Inc T.APLI

Alternate Symbol(s):  APLIF

Healthcare
Appili Therapeutics Inc. is a Canada-based biopharmaceutical company. The Company is advancing a diverse range of anti-infectives, including a vaccine candidate to eliminate a serious biological weapon threat, a topical antiparasitic for the treatment of a disfiguring disease, and a novel easy to use, liquid oral formulation targeting parasitic and anaerobic infections. The Company’s anti-infective product development portfolio includes three programs, including ATI-1701, ATI-1801 and ATI-1501. ATI-1701 is a novel, live-attenuated vaccine for Francisella tularensis (F. tularensis). ATI-1801 is a novel topical formulation of paromomycin (15% w/w) under advanced clinical development for the treatment of cutaneous leishmaniasis, a disfiguring infection of the skin that affects hundreds of thousands of people around the world annually. The ATI-1501 is a taste-masked liquid oral suspension formulation of the antibiotic metronidazole.


TSX:APLI - Post by User

Appili Therapeutics Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(49)
•••
Post by bmreedon Apr 04, 2022 10:25am
109 Views
Post# 34572853

Webinar w $APLI CEO Armand Balboni Fri Apr 8 @ 12:30PM ET

Webinar w $APLI CEO Armand Balboni Fri Apr 8 @ 12:30PM ET

Webinar - Appili Therapeutics (APLI) w/ CEO Dr. Armand Balboni

Fri, Apr 8 at 12:30pm ET / 9:30am PT

Q&A with Radius Research 

Register Here - https://us02web.zoom.us/webinar/register/5416488344066/WN_8nTWa3OVTWKjPW3pPJIXbw

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities